Inflammatory Bowel Disease Revisited: Newer Drugs

References

• Brandtzaeg P, Halstensen T S, Kett K, et al. Immu-nobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes. Gastroenterology 1989; 97: 1562–1584
   PubMed Web of Science ®Google Scholar
• Bjarnason I, O'Morain C, Levi A J, Peters TJ. Absorption of 51-chromium-labelled ethylene-diaminetetracetate in inflammatory bowel disease. Gastroenterology 1983; 85: 318–322
   PubMed Web of Science ®Google Scholar
• Hollander D, Vadheim C M, Brettholz E, Petersen G M, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 1986; 105: 883–885
   PubMed Web of Science ®Google Scholar
• Roediger W EW. The colonic epithelium in ulcerative colitis–an energy deficiency disease. Lancet 1980; 2: 712–714
   PubMed Web of Science ®Google Scholar
• Mayer L, Eisenhardt D. Defect in immuno-regulatory intestinal epithelial cells in inflammatory bowel disease. Inflammatory bowel disease: current status and future approach, RP MacDermott. Excerpta Medica, Amsterdam 1988; 9–16
   Google Scholar
• Podolsky DK. Glycoproteins in inflammatory bowel disease. Inflammatory bowel disease, G Jarnerot. Raven Press, New York 1987; 53–65
   Google Scholar
• Cope G F, Heatley R V, Kelleher J. Smoking and colonic mucus in ulcerative colitis. Br Med J 1986; 293: 481
   PubMed Web of Science ®Google Scholar
• Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989; 34: 1841–1854
   PubMed Web of Science ®Google Scholar
• Bjarnason I, Williams P, Smethurst P, Peters T J, Levi AJ. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 1986; 27: 1292–1297
   PubMed Web of Science ®Google Scholar
• Bjarnason I, Zanelli G, Smith T, et al. Nonsteroidal anti-inflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987; 93: 480–489
   PubMed Web of Science ®Google Scholar
• Roediger W EW, Deakin E J, Walker G, Nance SH. Assessment of salicylate derivatives for potential use in ulcerative colitis: proposal for a new action of 5-aminosalicyclic acid?. Pharmacology 1989; 39: 39–45
   PubMedGoogle Scholar
• McDonald G B, Jewell DP. Class II antigen (HLA-DR) expression by intestinal epithelial cells in inflammatory diseases of colon. J Clin Pathol 1987; 40: 312–317
   PubMedGoogle Scholar
• Mac Dermott R P, Stenson WA. Alterations of the immune system in ulcerative colitis and Crohn's disease. Adv Immunol 1988; 42: 285–322
   PubMedGoogle Scholar
• Dinarello CA. Interleukin-1 and its biologically related cytokines. Adv Immunol 1989; 44: 153
   PubMed Web of Science ®Google Scholar
• Smith KA. Interleukin-2. Annu Rev Immunol 1984; 2: 319–333
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Laursen L S, Bukhave K, Rask-Mad-Sen J. Inflammatory intermediaries in inflammatory bowel disease. Int J Colorectal Dis 1989; 4: 75–90
   PubMed Web of Science ®Google Scholar
• Vilaseca J, Salas A, Guamer F, Rodriquez R, Malagelada JR. Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology 1990; 98: 269–277
   PubMed Web of Science ®Google Scholar
• Grisham M B, Granger DN. Neurophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci 1988; 33: 6, S–15S
   PubMed Web of Science ®Google Scholar
• Bienenstock J, Denburg J, Scicchitano R, Stead R, Perdue M, Stanisz A. Role of neuropeptides, nerves and mast cells in intestinal immunity and physiology. Monogr Allergy 1988; 24: 134–143
   PubMedGoogle Scholar
• Svartz N. Sulfasalazine. II. Some notes on the discovery and development of salazoyrin. Am J Gastroenterol 1988; 83: 497–503
   PubMed Web of Science ®Google Scholar
• Klotz U. Clinical pharmacokinetics of sulfasalazine, its metabolites and other prodrugs of 5-aminosalicyclic acid. Clin Pharmacokinet 1985; 10: 285–302
   PubMed Web of Science ®Google Scholar
• Azad Khan A K, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 2: 892–895
   PubMed Web of Science ®Google Scholar
• Summers R W, Switz D M, Sessions JT, Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847–869
   PubMed Web of Science ®Google Scholar
• Malchow H, Ewe K, Brandes J W, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249–266
   PubMed Web of Science ®Google Scholar
• Allgayer H, Ahnfelt N O, Kruis W, et al. Colonic N-acetylation of 5-aminosalicyclic acid in inflammatory bowel disease. Gastroenterology 1989; 97
   Google Scholar
• Das K M, Eastwood M A, McManus J P, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973; 289: 491–495
   PubMed Web of Science ®Google Scholar
• Hanauer SB. 5-ASA enema therapy. Neth J Med 1989; 35: S11–S20
   PubMedGoogle Scholar
• Hanauer SB. Topical and oral aminosalicylates. The management of inflammatory bowel disease: new medical and surgical approaches, M Peppercorn. Marcel Dekker Publishers, New York 1990; 65–91
   Google Scholar
• Brogden R N, Sorkin EM. Mesalazine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs 1989; 38: 500–523
   PubMed Web of Science ®Google Scholar
• Jarnerot G. Newer 5-aminosalicyclic acid based drugs in chronic inflammatory bowel disease. Drugs 1989; 37: 73–86
   PubMed Web of Science ®Google Scholar
• Thomson A BR. On behalf of International Mesalazine Study Group, Coated oral 5-aminosalicyclic acid versus placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Ther 1990; 4: 55–64
   PubMedGoogle Scholar
• Hawthorne A B, Hawkey CJ. Immunosuppressive drugs in inflammatory bowel disease: a review of their mechanisms of efficacy and place in therapy. Drugs 1989; 38: 267–288
   PubMed Web of Science ®Google Scholar
• Holdstock G, Chastenay B F, Krawitt EL. Increased prostaglandin producing suppressor cells in inflammatory bowel disease not sensitive to sulfasalazine. Gastroenterology 1981; 80: 1177
   Google Scholar
• Gibson P R, Jewell DP. Sulphasalazine and derivatives, natural killer activity and ulcerative colitis. Clin Sci 1985; 69: 177–184
   Web of Science ®Google Scholar
• MacDermott R P, Schloemann S R, Bertovich M J, Nash G S, Peters M, Stenson WF. Inhibition of antibody secretion by 5-aminosalicyclic acid. Gastroenterology 1989; 96: 442–448
   PubMed Web of Science ®Google Scholar
• MacDermott R P, Schloemann S R, Bertovich M J, Nash G S, Peters M, Stenson WF. Inhibition of antibody secretion by 5-aminosalicyclic acid. Gastroenterology 1989; 96: 442–448
   PubMed Web of Science ®Google Scholar
• Cominelli F, Zipser R D, Dinarello CA. Sulfasalazine inhibits cytokine production in human mononuclear cells: a novel anti-inflammatory mechanism [Abstract]. Gastroenterology 1989; 96: A96
   Google Scholar
• Lamming C ED, Mahida Y R, Hawkey CJ. 5-aminosalicyclic acid (5-ASA) inhibits interleukin 1/3 (ILljS) production by colonic biopsies in organ culture [Abstract]. Gastroenterology 1989; 96: A285
   Google Scholar
• Nielsen O H, Bukhave K, Elmgreen J, Ahnfelt-Ronne I. Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1987; 6: 577–582
   Google Scholar
• Kaufman H J, Taubin HL. Nonsteroidal antiinflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987; 107: 513–516
   PubMed Web of Science ®Google Scholar
• Rampton D S, Sladen GE. Prostaglandin synthesis inhibitors in ulcerative colitis: flurbiprofen compared with conventional treatment. Prostaglandins 1981; 21: 417–425
   PubMed Web of Science ®Google Scholar
• Peskar B M, Dreyling K W, May B, Schaarschmidt K, Goebell H. Possible mode of action of 5-aminosalicyclic acid. Dig Dis Sci 1987; 32(12)51, S–56S
   Google Scholar
• Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984; 86: 453–460
   PubMed Web of Science ®Google Scholar
• Wallace J L, Keenan CM. A selective, orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of inflammatory bowel disease (IBD). Gastroenterology 1989; 96: A535
   PubMedGoogle Scholar
• Will P C, Weis W, Iverson L, et al. Intestinal antiinflammatory activity of ablucast (Ro 23-3544) in acetic acid (HOAc)-induced colitis in the rat. Gastoenterology 1989; 96: A546
   Google Scholar
• Eliakim R, Karmeli F, Razin E, Rachmilewitz D. Role of platelet activating factor in ulcerative colitis: enhanced production during active disease and inhibition by sulfasalazine and prednisolone. Gastroenterology 1988; 95: 1167–1173
   PubMed Web of Science ®Google Scholar
• Molin L, Standahl O. The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis. Acta Med Scand 1979; 206: 451–457
   PubMedGoogle Scholar
• Stenson W F, Mehta J, Spilberg I. Sulfasalazine inhibition of binding of N-formyl-methionyl-leu-cyl-phenylalanine (FMLP) to its receptor on human neutrophils. Biochem Pharmacol 1984; 33: 407–412
   PubMed Web of Science ®Google Scholar
• Craven P A, Pfanstiel J, Saito R, DeRubertis FR. Actions of sulfasalazine and 5-aminosalicyclic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity. Gastroenterology 1987; 92: 1998–2008
   PubMed Web of Science ®Google Scholar
• Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut 1987; 28: 190–195
   PubMed Web of Science ®Google Scholar
• Ahnfelt-Ronne I, Nielsen OH. The anti-inflammatory moiety of sulfasalazine, 5-aminosalicyclic acid, is a radical scavenger. Agents Actions 1987; 21: 191–194
   PubMedGoogle Scholar
• McIntyre P B, Macrae F A, Berghouse L, English J, Lennard-Jones JE. Therapeutic benefits from a poorly absorbed prednisolone enema in distal colitis. Gut 1985; 26: 822–824
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Clinical experience with tixocortol pivalate. Can J Gastroenterol 1988; 2(4)156–158
   Google Scholar
• Mulder C JJ, Rondas A ALM, Wiltink E HH, Tytgat G NJ. Topical corticosteroids in inflammatory bowel disease. Neth J Med 1989; 35: S27–S34
   Google Scholar
• Cupps T R, Fauci AS. Corticosteroid-mcdiated immunoregulation in man. Immunol Rev 1982; 65: 133–155
   PubMed Web of Science ®Google Scholar
• Kern J A, Lamb R J, Reed J C, Daniel R P, Nowell PC. Dexamethasone inhibition of interleukin 1 production by human monocytes. J Clin Invest 1988; 81: 237–244
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Laursen L S, Bukhave K, Rask-Mad-Sen J. In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis. Gut 1987; 28: 1095–1099
   PubMed Web of Science ®Google Scholar
• Present D H, Meltzer S J, Krumholz M P, et al. Short- and long-term toxicity to 6-mercaptopurine. A long-term randomized double blind study. N Engl J Med 1980; 302: 981–987
   PubMed Web of Science ®Google Scholar
• Present DH. 6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis. Management of inflammatory bowel disease. Gastroenterology Clinics of North America, AL Ginsberg. W.B. Saunders, Philadelphia 1989; Vol. 18.: 57–71
   Google Scholar
• Present D H, Meltzer S J, Krumholz M P, Wolke A, Bl Korelitz. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641–649
   PubMed Web of Science ®Google Scholar
• Elion GB. Biochemistry and pharmacology of purine analogues. Fed Proc 1967; 26: 898–904
   PubMedGoogle Scholar
• Dottan S, Glerstein S, Naveh N. Azathioprine induced in vitro inhibition of PGE2 production by rabbit retina. Prostaglandins 1987; 34: 271–275
   PubMedGoogle Scholar
• Brogan M, Hiserodt J, Oliver M, et al. The effects of 6-mercaptopurine on natural killer cell activities in Crohn's disease. J Clin Immunol 1985; 5: 204–211
   PubMed Web of Science ®Google Scholar
• Campbell A C, Skinner J M, Maclennan I CM, Her-Sey P, Waller CA. Immunosuppression in the treatment of inflammatory bowel disease. II. The effects of azathioprine on lymphoid cell populations in a double blind trial in ulcerative colitis. Clin Exp Immunol 1976; 24: 249–258
   PubMed Web of Science ®Google Scholar
• Leman B, Shanehan F, Targan S. Serial study of immunological alterations in patients with IBD on long-term treatment with 6-MP: effect on CTL. Gastroenterology 1988; 84: A255
   Google Scholar
• Gitnick G. Antibiotics and inflammatory bowel diseases. Management of inflammatory bowel disease. Gastroenterology Clinics in North America, AL Ginsberg. S.B. Saunders, Philadelphia 1989; Vol. 6.: 51–56
   Google Scholar
• Carbone JV. Broad-spectrum antibiotic therapy in Crohn's disease. Current management of inflammatory bowel disease. B.C. Decker, Philadelphia 1989; 207–210
   Google Scholar
• Kirsner J B, Shorter RG. Recent developments in 'nonspecific' inflammatory bowel disease. N Engl J Med 1982; 306: 775–785
   PubMed Web of Science ®Google Scholar
• Brandt L J, Bernstein L H, Boley S J, et al. Metronidazole therapy for perianal Crohn's disease: a follow-up study. Gastroenterology 1982; 83: 383–387
   PubMed Web of Science ®Google Scholar
• Singleton J. On behalf of Crohn's Flagyl Study Group. Metronidazole is more effective than placebo in treatment of active Crohn's disease. Gastroenterology 1989; 96: A477
   Google Scholar
• Ursing B, Aim T, Barany F, et al. A cooperative study of metronidazole and sulfasalazine for active Crohn's disease. The cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982; 83: 550–562
   PubMed Web of Science ®Google Scholar
• Gahr V, Ullmann U. The influence of metronidazole and its two main metabolites on murine in vitro lymphocyte transformation. Eur J Clin Microbiol 1983; 2: 568–570
   PubMedGoogle Scholar
• Grove D I, Mahmoud A AF, Warren KS. Suppression of cell-mediated immunity by metronidazole. Int Arch Allergy Appl Immunol 1977; 54: 422–427
   PubMedGoogle Scholar
• Banga J P, Barnett P S, Mahadevan D, McGregor AM. Immune recognition of antigen and its relevance to autoimmune disease: recent advances at the molecular level. Eur J Clin Invest 1989; 19: 107–116
   PubMed Web of Science ®Google Scholar
• Prytz H, Benoni C, Tagesson C. Does smoking tighten the gut?. Scand J Gastroenterol 1989; 24: 1084–1088
   PubMed Web of Science ®Google Scholar
• Harig J M, Soergel K H, Komorowski R A, Wood CM. Treatment of diversion colitis with short-chain fatty acid irrigation. New Engl J Med 1989; 320: 23–28
   PubMed Web of Science ®Google Scholar
• Breuer R I, Buto S K, Christ M L, et al. Short-chain fatty acids for distal ulcerative colitis [Abstract]. Gastroenterology 1990; 98
   Google Scholar
• Mayer L, Sachar DB. Efficacy of chloroquine in the treatment of inflammatory bowel disease [Abstract]. Gastroenterology 1988; 94: A293
   Web of Science ®Google Scholar
• Krogstad L J, Schlesinger PH. Acid-vesicle function, intracellular pathogens, and the action of chloroquine against Plasmodium falciparum. N Engl J Med 1987; 317: 543–549
   Google Scholar
• Bunch T W, O'Duffy J D, Tompkins R B, et al. Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis. Arthritis Rheum 1984; 27: 267
   PubMed Web of Science ®Google Scholar
• Kaplan M M, Knox T A, Arora S. Primary biliary cirrhosis treated with low-dose oral pulse methotrexate. Ann Intern Med 1988; 108: 429–431
   Google Scholar
• Kozarek R A, Patterson D J, Gelfand M D, Boto-Man V A, Ball T J, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353–356
   PubMed Web of Science ®Google Scholar
• Fedorak RN. Cyclosporine: Is there a role in inflammatory bowel disease?. Can J Gastroenterol 1988; 2: 1–4
   Google Scholar
• Allison M C, Pounder RE. Cyclosporin for Crohn's disease [Letter]. Lancet 1984; 1: 902–903
   PubMed Web of Science ®Google Scholar
• Bianchi P A, Modelli M, Quarto di Palo F, Ranzi T. Cyclosporin for Crohn's disease [Letter]. Lancet 1984; 2: 1242
   PubMedGoogle Scholar
• Lichtiger S, Present DH. Cyclosporin A in the treatment of severe, refractory ulcerative colitis [Abstract]. Gastroenterology 1989; 96: A301
   Google Scholar
• Brynshov J, Greund L, Rasmussen S N, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989; 321: 845–850
   PubMedGoogle Scholar
• Krensky A M, Weiss A, Crabtree G, Davis M M, Parham P. T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 1990; 322: 510–517
   PubMed Web of Science ®Google Scholar
• Starzl T E, Fung J, Venkataramman R, Todo S, Demetris A J, Jain A. FK 506 for liver, kidney and pancreas transplantation. Lancet 1989; 2: 1000–1004
   PubMed Web of Science ®Google Scholar
• O'Garra A. Interleukins and the immune system 2. Lancet 1989; 1: 1003–1005
   PubMed Web of Science ®Google Scholar
• Donowitz M. Arachidonic acid metabolites and their role in inflammatory bowel disease: an update requiring addition of a pathway. Gastroenterology 1985; 88: 580–587
   PubMed Web of Science ®Google Scholar
• Hawkey C J, Rampton DS. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment?. Gastroenterology 1985; 189: 1162–1188
   Google Scholar
• Laursen L S, Naesdal J, Bukhave K, Lauritsen K, Rask-Madsen J. Selective 5-lipoxygenase inhibition in patients with ulcerative colitis: Effects of Abbott-64077 [Abstract]. Gastroenterology 1990; 98
   Google Scholar
• Kinsella J E, Lokesh B, Broughton S, Whelan J. Dietary polyunsaturated fatty acids and eico-sanoids: potential effects on the modulation of inflammatory and immune cells: an overview. Nutrition 1990; 6: 24–44
   PubMed Web of Science ®Google Scholar
• Sperling R I, Austen KF. Polyunsaturated fatty acids and eicosanoids. Effects of omega-3 polyunsaturated fatty acids on human leukocyte 5-lipoxygenation and function, WEM Lands. American Oil Chemists Society, Biloxi, Miss 1987; 115
   Google Scholar
• Endres S, Ghorbani R, Kelley V E, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320: 265
   PubMed Web of Science ®Google Scholar
• McCall T B, O'Leary D, Bloomfield J, O'Morain CA. Therapeutic potential of fish oil in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1989; 3: 415–424
   PubMed Web of Science ®Google Scholar
• Stenson W F, Cort D, Beeken W, Rodgers J, Burakoff R. A trial of fish oil supplemented diet in ulcerative colitis [Abstract]. Gastroenterology 1990; 98
   Google Scholar
• Hawthorne A B, Daneshmend T K, Hawkey C J, et al. Fish oil in ulcerative colitis: final results of a controlled clinical trial [Abstract]. Gastroenterology 1990; 98
   Google Scholar
• Koningsberger J C, Marx J JM, Van Hattum J. Free radicals in gastroenterology: a review. Scand J Gastroenterol 1988; 23: 30–40
   Web of Science ®Google Scholar
• Parks DA. Oxygen radicals: mediators of gastrointestinal pathophysiology. Gut 1989; 30: 293–298
   PubMed Web of Science ®Google Scholar
• Petkau A. Scientific basis for the clinical use of superoxide dismutase. Cancer Treatment Rev 1986; 13: 17–44
   PubMed Web of Science ®Google Scholar
• Emerit I, Emerit J, Leug A, Beck M. Chromosomal breakage in Crohn's disease: anticlastogenic effect of D-penicillamine and L-cysteine. Human Genetics 1972; 16: 313–322
   Google Scholar
• Bennett JD. Use of alpha-tocopherylquinone in the treatment of ulcerative colitis. Gut 1986; 27: 695
   PubMedGoogle Scholar
• Kooh T R, Carney I A, Go V LW. Distribution and quantitation of gut neuropeptides in normal intestine and inflammatory bowel diseases. Dig Dis Sci 1987; 32: 369–376
   PubMedGoogle Scholar
• Mantyh C R, Gates T S, Zimmerman R P, et al. Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn's disease. Proc Natl Acad Sci USA 1988; 85: 3235–3239
   PubMedGoogle Scholar
• Shanahan F, Anton P. Neuroendocrine modulation of the immune system. Possible implications for inflammatory bowel disease. Dig Dis Sci 1988; 33: 41, S–49S
   PubMedGoogle Scholar
• Lechin F, van der Dijs B, Insausti C L, et al. Treatment of ulcerative colitis with clonidine. J Clin Pharmacol 1985; 25: 219–226
   PubMedGoogle Scholar